Parkin is not required to sustain OXPHOS function in adult mammalian tissues
Authors:
- Roberta FilogranaRFRoberta Filograna
- Jule GerlachJGJule Gerlach
- Hae-Na ChoiHCHae-Na Choi
- Giovanni RigoniGRGiovanni Rigoni
- Michela BarbaroMBMichela Barbaro
- Mikael OscarsonMOMikael Oscarson
- Seungmin LeeSLSeungmin Lee
- Katarina TiklovaKTKatarina Tiklova
- Markus RingnérMRMarkus Ringnér
- Camilla KoolmeisterCKCamilla Koolmeister
- Rolf WibomRWRolf Wibom
- Sara RiggareSRSara Riggare
Preprint
Abstract
Loss-of-function variants in the PRKN gene encoding the ubiquitin E3 ligase PARKIN cause autosomal recessive early-onset Parkinson’s disease (PD). Extensive in vitro and in vivo studies have reported that PARKIN is involved in multiple pathways of mitochondrial quality control, including mitochondrial degradation and biogenesis. However, these findings are surrounded by substantial controversy due to conflicting experimental data. In addition, the existing PARKIN-deficient mouse models have failed to faithfully recapitulate PD phenotypes. Therefore, we have investigated the mitochondrial role of PARKIN during ageing and in response to stress by employing a series of conditional Parkin knockout mice. We report that PARKIN loss does not affect oxidative phosphorylation (OXPHOS) capacity and mitochondrial DNA (mtDNA) levels in the brain, heart, and skeletal muscle of aged mice. We also demonstrate that PARKIN deficiency does not exacerbate the brain defects and the pro-inflammatory phenotype observed in mice carrying high levels of mtDNA mutations. To rule out compensatory mechanisms activated during embryonic development of Parkin -deficient mice, we generated a mouse model where loss of PARKIN was induced in adult dopaminergic (DA) neurons. Surprisingly, also these mice did not show motor impairment or neurodegeneration, and no major transcriptional changes were found in isolated midbrain DA neurons. Finally, we report a patient with compound heterozygous PRKN pathogenic variants that lacks PARKIN and has developed PD. The PARKIN deficiency did not impair OXPHOS activities or induce mitochondrial pathology in skeletal muscle from the patient. Altogether, our results argue that PARKIN is dispensable for OXPHOS function in adult mammalian tissues.Keywords
All Related Versions
- Published version: npj Parkinson's Disease, 10 (1), 1.
This publication has 74 references indexed in Scilit:
- Muscle Biopsy2021
- EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2020
- Molecular characterization of PRKN structural variations identified through whole‐genome sequencingMolecular Genetics & Genomic Medicine, 2018
- A novel histochemistry assay to assess and quantify focal cytochrome c oxidase deficiencyThe Journal of Pathology, 2018
- Genotype‐Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic ReviewMovement Disorders, 2018
- Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to FBXL4 mutationsJournal of Inherited Metabolic Disease, 2015
- Mutations in FBXL4, Encoding a Mitochondrial Protein, Cause Early-Onset Mitochondrial EncephalomyopathyThe American Journal of Human Genetics, 2013
- Systematic Review and UK‐Based Study of PARK2 (parkin), PINK1, PARK7 (DJ‐1) and LRRK2 in early‐onset Parkinson's diseaseMovement Disorders, 2012
- Decline of striatal dopamine release in parkin‐deficient mice shown by ex vivo autoradiographyJournal of Neuroscience Research, 2006
- Genetics of parkin-linked diseaseHuman Genetics, 2004